Merck & Co (MRK)

133.72
+0.91 (0.69%)
NYSE · Last Trade: Nov 21st, 1:59 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech, met its primary endpoint of overall survival (OS) compared to treatment of physician’s choice (TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel) in the treatment of patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy. TroFuse-015 represents the first time a TROP2-directed ADC has demonstrated an OS benefit in a global Phase 3 trial in this patient population, where there is significant unmet need. These data will be presented at an upcoming medical meeting and shared with regulatory authorities.
By Merck & Co., Inc. · Via Business Wire · November 20, 2026
Merck and Isomorphic Labs Enter Strategic Research Collaboration
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs’ AI approach to drug discovery with Merck’s rich proprietary data resources and deep discovery experience.
By Merck & Co., Inc. · Via Business Wire · November 19, 2026
Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Thomas H. Glocer intends to retire from the Merck Board of Directors at the Company’s Annual Meeting of Shareholders in May 2027. The independent members of the Board have appointed Douglas M. Baker, Jr., as independent lead director, effective Jan. 1, 2027, succeeding Mr. Glocer in the role.
By Merck & Co., Inc. · Via Business Wire · November 18, 2026
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and other hematologic malignancies in the BELLWAVE program.
By Merck & Co., Inc. · Via Business Wire · November 17, 2026
Merck Announces First-Quarter 2027 Dividend
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.88 per share of the company’s common stock for the first quarter of 2027. Payment will be made on January 8, 2027, to shareholders of record at the close of business on December 15, 2026.
By Merck & Co., Inc. · Via Business Wire · November 17, 2026
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab) to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age at increased risk for severe RSV disease through their second RSV season. The CHMP recommendation will now be reviewed by the European Commission (EC) for marketing authorization in the European Union (EU), Iceland, Liechtenstein and Norway, and a final decision is expected in the next two months.
By Merck & Co., Inc. · Via Business Wire · November 13, 2026
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This recommendation will now be reviewed by the European Commission (EC) for marketing authorization in the European Union (EU), Iceland, Liechtenstein and Norway. A final decision is expected in the next two months.
By Merck & Co., Inc. · Via Business Wire · November 13, 2026
Merck to Participate in the Jefferies Global Healthcare Conference in London
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, Nov. 19, 2026, at 11:00 a.m. GMT / 6:00 a.m. ET.
By Merck & Co., Inc. · Via Business Wire · November 12, 2026
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company’s Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide (4 mg, 7 mg and 10 mg), an investigational injectable GLP-1/glucagon receptor co-agonist, versus placebo for the treatment of adults with MASH and stage F2 or F3 liver fibrosis. The findings were presented during a late-breaking abstract session at The Liver Meeting (TLM), being held in Denver, Colo., and simultaneously published in The Lancet.
By Merck & Co., Inc. · Via Business Wire · November 9, 2026
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care (SOC) with a history of exacerbations. Recruitment of the ENHANCE-3 trial has begun, and the first patients are now enrolling in the United States.
By Merck & Co., Inc. · Via Business Wire · November 3, 2026
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data across its HIV treatment and prevention pipeline and portfolio will be presented at HIV Drug Therapy Glasgow 2026 (HIV Glasgow 2026), taking place Nov 8–11, 2026, in Glasgow, Scotland. Presentations will highlight Merck’s strategy to expand oral options in both HIV treatment and prevention, including data on once-daily IDVYNSO® (doravirine/islatravir), the investigational once-weekly oral treatment regimens islatravir/lenacapavir (ISL/LEN) and islatravir/ulonivirine (ISL/ULO), and the investigational once-monthly oral pre-exposure prophylaxis (PrEP) alimatravir (AMI, MK-8527).
By Merck & Co., Inc. · Via Business Wire · November 2, 2026
Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop
Investors who lost money on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Merck & Co., Inc.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · October 30, 2026
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline
Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the Company may have violated the federal securities laws. The investigation comes after an October 22, 2026 disclosure concerning Merck & Co., Inc.
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 1.76% Stock Decline
Merck & Co., Inc. ("Merck" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Merck & Co., Inc. (NYSE: MRK), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Merck & Co., Inc. on October 22, 2026.
By The Law Offices of Frank R. Cruz · Via Business Wire · October 29, 2026
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2026.
By Merck & Co., Inc. · Via Business Wire · October 29, 2026
KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 KEYNOTE‑C93 trial, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence after receiving prior adjuvant therapy. Results showed KEYTRUDA as monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) for these patients, reducing the risk of disease progression or death by 43% (HR=0.57; [95% CI, 0.42-0.79]; p=0.0002) compared to platinum doublet chemotherapy. These late-breaking results will be presented today during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 [Presentation #LBA12], were selected for an official ESMO press briefing and were published simultaneously in The Lancet.
By Merck & Co., Inc. · Via Business Wire · October 26, 2026
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) being developed in collaboration with Kelun-Biotech, in patients with advanced or recurrent endometrial cancer who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy. At a pre-specified interim analysis, the study demonstrated statistically significant and clinically meaningful improvement in its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as well as its key secondary endpoint of objective response rate (ORR) compared with treatment of physician’s choice (TPC; doxorubicin or paclitaxel). TroFuse-005 is the first global Phase 3 trial and the first ADC to demonstrate statistically significant improvement in both OS and PFS compared to chemotherapy for these patients with advanced or recurrent endometrial cancer. These late-breaking data will be presented for the first time today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2026 [Presentation #LBA11], were selected for an official ESMO press briefing, and were published simultaneously in The Lancet.
By Merck & Co., Inc. · Via Business Wire · October 26, 2026
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.
By Biotech Insider · Via GlobeNewswire · October 26, 2026
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as adjuvant treatment for patients with completely resected stage IIB-IV melanoma. These late-breaking results will be presented for the first time during Presidential Symposium I at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation #LBA1), were selected for an official ESMO Press Briefing and have been accepted for publication in The New England Journal of Medicine.
By Merck & Co., Inc. · Via Business Wire · October 22, 2026
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.
By FN Media · Via GlobeNewswire · October 21, 2026
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END
Via FinancialNewsMedia · October 21, 2026
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invasive bladder cancer (MIBC). This approval, which also covers KEYTRUDA SC® [known as KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.], marks the first and only PD-1 inhibitor plus antibody-drug conjugate (ADC) regimen available for patients with MIBC regardless of cisplatin eligibility in the European Union (EU).
By Merck & Co., Inc. · Via Business Wire · October 21, 2026
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Paul J. Diaz, managing partner at Cressey & Company, will join the Company’s Board of Directors effective Nov. 1, 2026. He will stand for election by the company’s shareholders in May 2027. With the addition of Mr. Diaz, the Merck board will consist of 14 members.
By Merck & Co., Inc. · Via Business Wire · October 13, 2026
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential Symposia at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain from Oct. 23-27. Additionally, more than 90 additional abstracts across more than 20 tumor types from the company’s pipeline and portfolio will be presented throughout the meeting.
By Merck & Co., Inc. · Via Business Wire · October 13, 2026
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in New Orleans: BRUNELLO - 1-Year Pivotal Trial Results of Remigromig (MK-3000, formerly EYE103) for the Treatment of Diabetic Macular Edema; D. D'Amico.
By Merck & Co., Inc. · Via Business Wire · October 10, 2026